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SUMMARY
Objective: To report on the early experience with the treatment of
neovascular AMD with intravitreal injection of bevacizumab
(Avastin) in Nigeria.
Materials and Methods: Eight eyes (7 patients) with neovascular
AMD who met the inclusion criteria were treated with
intravitreal 1.25mg bevacizumab between September 2008 and
May 2009. Injections were given every 4-6 weeks. In total, 2–4
injections were given. One patient had bilateral treatment. All
the patients were regularly followed up until December 2009. 
Results: The presenting visual acuity ranged from light perception
(LP) to counting fingers (CF). In 2 patients (2 eyes) their
visual acuity improved 2 weeks after injection from CF to 6/36
and remained stable for 4 months. In another 2 patients (2
eyes) acuity improved from LP to CF. In yet 2 other patients (4
eyes) the visual acuity remained unchanged (HM in 2 eyes; CF
in 2 eyes) after 9 months and 4 injections. Clinically the
subretinal blood was observed to resolve, albeit slowly, in all
 the patients within 2 months from the start of treatment.
Conclusions: This preliminary experience suggests that intravitreal
bevacizumab is safe and beneficial in Nigerian Africans with
neovascular AMD. However careful patient selection, regular
follow up and aseptic injection techniques are advised when
treating these patients.
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INTRODUCTION
Age-related macular degeneration (AMD) is seen commonly among
the elderly in Nigeria.  At the Guinness Eye Center Onitsha it1,2
constitutes 19.4% of retinal diseases.  A community-based study in3
Anambra State showed that it is the second most common cause of
blindness in patients aged above 50 years.  The neovascular form of4
the disease causes most of the blindness.5
In 2006 the use of monoclonal antibody, an inhibitor of vascular
endothelial growth factor (anti-VEGF), ranibizumab (LucentisTM
Genentech California) for treatment of neovascular AMD was
approved in the United States of America.  Cost issues even in6
developed countries led to the off-label use of the related drug,
bevacizumab (Avastin  Genentech, California).  Bevacizumab is theTM 6
parent compound of ranibizumab. These drugs are not yet widely
used in Nigeria.
The objective of this article is to report on the early experience
with the treatment of neovascular AMD with intravitreal injection of
bevacizumab (Avastin) in Nigerian Africans.
MATERIALS AND METHODS
Eight eyes (7 patients) with neovascular AMD were treated with
intravitreal injections of 1.25mg bevacizumab between September
2008 and May 2009. Criteria for selection for treatment included
subretinal hemorrhage, and retinal pigment epithelial degeneration
in the posterior pole in a person 50 years or older for which there
is no other retinal vascular disease to account for these  features.
Patients with pigment epithelial detachment were not injected with
bevacizumab and so were excluded from this study. The selected
patients had complete ocular examination including visual acuity test,
slit lamp examination of the anterior segment, applanation
tonometry, slit lamp fundus examination with 78D noncontact lens
and indirect ophthalmoscopy.
The injection was given in the operation room under strict
aseptic conditions. Anesthesia was given in the form of
subconjunctival injection of 2% xylocaine injection in the part of the
eye chosen for the intravitreal injection. The intravitreal injections
were given with insulin syringe and 25G needle 4mm from the
limbus in the temporal or inferior temporal quadrant. Anterior
chamber paracentesis was also performed during the injection using
another 25G needle. 
Injections were given every 4-6 weeks in accordance with the
recommendations of previous studies.  In total, 2 – 4 injections were6
given. One patient had bilateral treatment. All the patients were
regularly followed up to December 2009. The patients were
followed up as follows: 1 day post injection; 2 weekly until injection
was stopped; then 6 weekly. Follow-up examination included visual
acuity test, slit lamp examination of the anterior segment,
applanation tonometry, slit lamp fundus examination with 78D
noncontact lens and indirect ophthalmoscopy. We did not have
facilities for fluorescein angiography or optical coherence




The presenting visual acuity ranged light perception (LP) to counting
fingers (CF). In 2 patients (2 eyes) visual acuity improved 2 weeks
after injection from CF<1/2m to 6/36 and remained stable for 4
months. In another 2 patients (2 eyes) visual acuity improved from
LP to CF. In yet 2 other patients (4 eyes) the visual acuity remained
unchanged (HM in 2 eyes; CF in 2 eyes) after 9 months and 4
injections. The intraocular pressures were within normal limits
before the injections (10 -16mmHg) and throughout the follow up
period (10-17mmHg). Only in one patient had a slight rise in the
IOP from 15mmHg pre-injection to 17mmHg at the last follow-up
visit. 
No untoward effects such as retinal detachment or raised
intraocular pressure or endophthalmitis was observed. Clinically the
subretinal blood was observed to resolve, albeit slowly, in all the
patients within 2 months of the commencement of treatment. 
DISCUSSION
Our initial observation suggests that intravitreal bevacizumab is safe
and effective in the treatment of neovascular AMD in Nigerian
Africans. This is similar to the experience in developed countries
where the drug is widely used. (It should be stressed that
bevacizumab is officially approved for colonic cancer  and that its6
cousin, ranibizumab, is the approved drug for treating retinal
vascular disorders.  However cost issues even in developed countries6
led to off-label use of bevacizumab.)
The improvement in acuity in the patients was rapid, occurring
within 2 weeks of injection. However it is clear from this small series
that although 50% of the eyes had improved Snellen visual acuity of
2 or more lines, another half never had any improvement in spite of
multiple injections. Further studies are required to find which patient
is more likely to benefit from this treatment in our environment. This
study is limited by the non-availability of facilities for fluorescein
angiographic studies in the patients.  In spite of being cheaper than
ranibizumab, bevacizumab is still beyond the reach of many patients
who would benefit from it in our hospital. A deliberate policy of
making bevacizumab and ranibizumab available in public hospitals
will be of benefit to many patients with intraocular neovascular
disease and widen the experience of the treating physicians. 
Another drawback is that some patients are not comfortable
with repeated injections. Intravitreal injection is associated with risk
of endophthalmitis and retinal detachment. Adverse cardiovascular
events have also been associated with bevacizumab. But none of
these were encountered in this series. However it should be
cautioned that the small number of patients in our initial experience
does not allow for definitive conclusions with regard to
complications. 
In conclusion, this preliminary experience suggests that
intravitreal bevacizumab is safe and beneficial in Nigerian Africans
with neovascular AMD. However, careful patient selection, regular
follow-up and aseptic injection techniques are advised when treating
these patients.
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